JAKJAK

Back to Disease

November 2024

Journal Club Review: Safety and Efficacy of Upadacitinib for Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase-1 Trial

October 2024

Journal Club Review: Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

October 2024

Medication Review: What Is the Safety Profile of Upadacitinib Across Indications?

September 2024

Medication Review: How Is Upadacitinib Dosed Across Rheumatologic Indications?

September 2024

Medication Review: Describe the Mechanism of Action of Upadacitinib

October 2024

FAQ: Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies

October 2024

FAQ: What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?

October 2024

FAQ: Variability in JAK Inhibition Specificity & Its Clinical Implications

September 2024

FAQ: Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease

September 2024

FAQ: Describe JAK-STAT signaling in inflammation

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play